Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

This trial is testing whether adding orelabrutinib (a BTK inhibitor) to the standard chemotherapy regimen of bendamustine and rituximab can improve outcomes for people newly diagnosed with mantle cell lymphoma — a rare and aggressive blood cancer. **You may be eligible if...** - You are 18 or older with a new diagnosis of mantle cell lymphoma confirmed by flow cytometry or biopsy - You have not received any prior treatment for this cancer - Your cancer is Stage II–IV (or Stage II requiring systemic treatment) - You are in reasonably good physical condition (ECOG 0–2) - You have at least one of the following high-risk features: high MIPI score, Ki67 above 50%, TP53 abnormality, or blastic/pleomorphic variant **You may NOT be eligible if...** - You have previously received treatment for mantle cell lymphoma - You have active brain involvement of your lymphoma - You have serious organ dysfunction, active infections, or autoimmune conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.